9th Ace Clinical Trials Summit San Diego US 2027

9th Ace Clinical Trials Summit San Diego US 2027 is organized by ACE Expo LTD and will be held from May 05 - 06, 2027 at Marriott Marquis San Diego Marina, San Diego, California, United States of America.

Description:
The 9th Ace Clinical Trials Summit USA 2027 brings together leading experts, innovators, and stakeholders to explore cutting-edge advancements shaping the future of clinical research. With a strong focus on AI integration, patient-centric approaches, decentralized trials, real-world evidence, and sustainable practices, the summit will deliver two impactful days of presentations, panel discussions, and business meetings. Key themes include digital transformation, generative AI in recruitment, ethical challenges in tech-enabled trials, and the evolving role of data and technology in global operations. Delegates will engage in in-depth conversations around rare diseases, patient engagement, and blockchain applications, driving forward innovation in clinical development. The summit provides unparalleled networking opportunities and actionable insights for CROs, sponsors, biotech firms, and regulatory professionals looking to accelerate trial efficiency, enhance patient outcomes, and transform clinical operations for the future. Join us to shape what’s next in clinical trials.

Conference Themes:
05th May

• Next-Generation Drug Discovery and Molecular Design
• Biomarker Discovery for Precision Oncology
• Next Generation Target Discovery through AI
• Translational Research in the Era of Precision Medicine
• Targeting Neurological Diseases through Gene Therapy Approaches
• The Evolution of in vitro models
• Transforming RNA Target Identification with Bioinformatics

06th May

• Computational Medicinal Chemistry for Lead Optimization
• Novel approaches for cell & gene therapy
• Sustainable Practices in Medicinal Chemistry
• In-silico Drug Design
• Advancing ADC Development Through AI-Based PBPK Modeling
• How successful are AI/ML Approaches in Drug Development
• Next Generation Target Discovery through AI